FORE Biotherapeutics Announces $75M in Series D Financing and CEO Transition
FORE Biotherapeutics today announced the closing of its $75 million Series D financing, led by the SR One and co-led by Medicxi and joined by existing investors. FORE Biotherapeutics’ syndicate now includes new investor Medicxi, as well as existing investors OrbiMed, HBM Healthcare Investments, Novartis Venture Fund, 3B Future Health Fund, Cormorant Asset Management, Wellington Management and Samsung Securities. In connection with the financing, Giovanni Mariggi, Partner at Medicxi, was appointed to FORE Biotherapeutics’ Board of Directors.
“At SR One, we invest in companies turning truly innovative discoveries into transformational new therapies in areas with significant unmet clinical needs,” said Matthew Foy, Partner at SR One. “FORE Biotherapeutics is well-positioned to deliver on the promise of plixorafenib, which has demonstrated promising single-agent activity against BRAF-altered tumors, including primary central nervous system tumors. We look forward to continuing to support the company as it further progresses its ongoing Phase 2 FORTE global, registrational trial.”
Proceeds from the financing will be used to accelerate the development of plixorafenib, the company’s novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations. Positive updated data from the Phase 1/2a trial evaluating plixorafenib in patients with BRAF-altered advanced solid and central nervous system tumors were recently presented at the American Society of Clinical Oncology (ASCO) meeting. Plixorafenib demonstrated both promising antitumor activity with durable responses and favorable tolerability as a single agent in patients with advanced BRAF-altered tumors.
In conjunction with the Series D financing, Matthew E. Ros will step down from his role as Chief Executive Officer and member of the Board of Directors to redirect his energy toward other professional pursuits, effective September 1, 2023. Shawn M. Leland, PharmD, RPh, current advisor to SR One and former Founder, President, and Chief Executive Officer of Elevation Oncology, has been appointed to the Board of Directors and will transition into the role of interim Chief Executive Officer overseeing the day-to-day activities of the company in collaboration with the management team, until a CEO successor is identified.
“On behalf of the Board of Directors, I would like to sincerely thank Matt for his leadership, dedication and many contributions toward the advancement of plixorafenib to its next seminal phase of clinical development,” said Dieter Weinand, Chairman of the Board of FORE Biotherapeutics. “We welcome Shawn as interim CEO and Board member as we enter this next phase of growth for the company. We are also thrilled to welcome Giovanni to our Board as his expertise will be invaluable in advancing the clinical development strategy for plixorafenib.”
About Plixorafenib
Plixorafenib is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF. It was designed to target a wide range of BRAF mutations while sparing wild-type forms of RAF. Preclinical studies and clinical trials have shown that its unique mechanism of action effectively inhibits not only the constitutively active BRAFV600 monomers targeted by first-generation RAF inhibitors but also disrupts constitutively active dimeric BRAF class 2 mutants, fusions, splice variants and other alterations found in a range of cancers. Unlike first-generation RAF inhibitors, plixorafenib does not induce paradoxical activation of the RAF/MEK/ERK pathway. As a “paradox breaker,” plixorafenib could therefore treat acquired resistance to current RAF inhibitors and, more generally, yield improved safety and more durable efficacy than first-generation RAF inhibitors.
About FORE Biotherapeutics
FORE Biotherapeutics is a precision oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients. Its lead asset plixorafenib is a Class 1/V600 and 2 BRAF inhibitor with demonstrated clinical safety and early efficacy signals in the previous Phase 1/2a clinical trial. Leveraging a proprietary functional genomics platform that can screen a wide range of known mutations for cancer-driving genes, the FORE R&D team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without adequate treatment options. For more information, please visit www.fore.bio or follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230823553491/en/
Contact information
Investors and Media:
Argot Partners
212.600.1902 | ForeBio@argotpartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Flatworld Solutions Announces New Logo and Purpose statement4.10.2023 16:00:00 EEST | Press release
On October 3rd, Flatworld Solutions, a global outsourcing titan, revealed a transformative shift in its brand identity. Flatworld Solutions’ iconic infinity symbol transformed into a modern whirl motif to reflect its ever-progressive essence, symbolising the company's agility and readiness to tap into the emerging possibilities of GAI and automation. Flatworld Solutions propelled by its enthusiastic 5000+ “Possibilitarians” dramatically scaled its presence in the global market for almost two decades now. This, while embracing the global multi-location delivery hubs and technological innovation. A comprehensive outsourcing powerhouse, Flatworld offers an expansive suite of over 14 services, adeptly catering to diverse business needs across the globe. Flatworld Solutions began its global operations in 2004 and has since become a value-driven partner for businesses worldwide. Executing over a million projects and harnessing the power of search engine marketing to leverage demands of globa
Canva Celebrates 10th Anniversary With Launch of World’s First All-In-One AI Design Offering for Everyone and Every Business4.10.2023 16:00:00 EEST | Press release
Canva, the world’s only all-in-one visual communication platform, celebrates 10 years of innovation with the launch of Canva’s Magic Studio. Reinforcing Canva’s mission to democratize design, Magic Studio is the world’s most comprehensive AI-design platform empowering individuals, teams and organizations to boost their creativity, supercharge their productivity and scale their brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231004078842/en/ Canva, the world’s only all-in-one visual communication platform, celebrates 10 years of innovation with the launch of Canva’s Magic Studio. (Graphic: Business Wire) “A decade ago, Canva set out to empower the world to design by simplifying a complex and fragmented design ecosystem. As we go into the next decade of our journey, we’re incredibly excited to be taking a massive leap forward with the launch of Magic Studio – the first all-in-one suite of design AI tools created to supe
OPEX® Infinity® Warehouse Automation Solution Wins Gold 2023 Merit Award for Technology in Robotics Category4.10.2023 16:00:00 EEST | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing solutions for warehouse and document and mail automation has won a Gold 2023 Merit Award for technology in the category of Robotics for the company’s Infinity® automated storage and retrieval system (AS/RS). The Infinity AS/RS is the most advanced goods-to-person (G2P) technology solution available in warehouse automation. Designed to reduce labor challenges, drive order accuracy, maximize existing space, and scale to meet demand, the Infinity AS/RS features unparalleled storage density, configurability, and flexibility to help ecommerce clients increase productivity and throughput. Infinity’s iBOT® wireless robotic vehicles travel under the storage structure and pass through the aisles, minimizing distance and saving time. “We are proud to have won this award for our Infinity system,” said Alex Stevens, President, Warehouse Automation at OPEX, which has been family-owned and operated for nearly 50 years. “At OP
Boomi Unveils Redesigned OEM and Embedded Partner Program for Software Providers4.10.2023 16:00:00 EEST | Press release
Boomi™, the intelligent connectivity and automation leader, today introduced at its Silicon Valley Boomi Partner Summit a new Boomi Partner Program for Software Providers, offering an accelerated way to go to market with Boomi, engage with customers, and scale business. The new program introduces multiple pre-configured integration packages structured for easy entry-to-market and quick time to value for partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231004548984/en/ Boomi Unveils Redesigned OEM and Embedded Partner Program for Software Providers (Graphic: Business Wire) “As we continually look for ways to better serve our partners, I’m thrilled to introduce an improved program to help software providers drive additional value,” said Dan McAllister, Senior Vice President of Global Alliances and Channels at Boomi. “We’ve carefully designed the program to help providers make new connections to their customers, and del
Boomi Pay-As-You-Go Now Available in AWS Marketplace4.10.2023 16:00:00 EEST | Press release
Boomi™, the intelligent connectivity and automation leader, today announced that Boomi Pay-As-You-Go, a self-serve, pay-as-you-go edition of the Boomi platform, is now available in AWS Marketplace, a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy, and deploy software that runs on Amazon Web Services (AWS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231004095285/en/ Boomi Pay-As-You-Go Now Available in AWS Marketplace (Graphic: Business Wire) With a standard monthly fee and usage-based pricing, Boomi Pay-As-You-Go gives AWS customers full access and freedom to explore all services of the award-winning Boomi platform with no annual subscriptions or long-term contracts required. Services within Boomi Pay-As-You-Go include: Integration, API Management, Master Data Hub, Flow, B2B/EDI Management, and Event Streams. As a low-cost, low risk option for de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom